Novartis AG (NVS)
- Sector
- Pharmaceuticals
- Last price
- $156.08
- As of
Kresmion compiles this page from NVS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
NOVARTIS AG (NVS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-27.
See the full NVS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NVS on one page. Preview it with sample data, then open it live with a free account.
Preview the NVS dossierActive events for NVS
- high13F: funds reduced
3 tracked funds reduced NVS this 2026Q2, institutional consensus
- high13F: funds added
4 tracked funds increased NVS this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +170% to NVS (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +79% to NVS (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +1786% to NVS (2026Q2)
FREE, NO ACCOUNT
Every event on NVS, as it fires
You are seeing 5 of 22 events recorded on NVS since 2026-05-31.
The five above landed across 2 days. The other 17 were recorded on 3 other days. 17 of the 22 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NVS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 66987V109 · 2026Q2 | $123.5M | 0.17% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 66987V109 · 2026Q2 | $118.8M | 0.04% | , |
| CITADEL ADVISORS LLCCUSIP 66987V109 · 2026Q2 | $50.3M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 66987V109 · 2026Q2 | $16.6M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 66987V109 · 2026Q2 | $2.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NVS
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
NVS against its peers
NVS's operating margin of 32.4% ranks in the 91st percentile of 16 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-28 and 2025-12-31.
| Metric | NVS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 54.5B USD | 5.2B USD | 76 | 22 |
| Revenue YoY | 8.4% | n/a | n/a | 3 |
| Gross margin | n/a | 73.4% | n/a | 16 |
| Operating margin | 32.4% | 10.5% | 91 | 16 |
| Net margin | 25.6% | 8.9% | 77 | 23 |
| Return on equity | 30.0% | 15.4% | 69 | 23 |
| P / E | n/a | 21.6x | n/a | 13 |
| 1 year | 26.5% | 41.5% | 45 | 9 |
Peers (25): AZN, MRK, NVO, PFE, JNJ, BMY, GSK, LLY, TEVA, ZTS, VTRS, JAZZ, CORT, AXSM, AMRX, LQDA, OGN, AMLX, TARS, BHC, SUPN, HRMY, XERS, TRVI, ANIP. Fiscal periods ending between 2025-12-28 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NVS: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NVS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NVS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.